Article Text

PDF
Efficacy of infliximab in the treatment of Erdheim-Chester disease
  1. Fleur Cohen-Aubart1,2,
  2. Philippe Maksud2,3,
  3. Jean-François Emile4,
  4. Neila Benameur5,
  5. Frédéric Charlotte2,6,
  6. Philippe Cluzel2,7,
  7. Zahir Amoura1,2,
  8. Julien Haroche1,2
  1. 1 Internal Medicine Department 2, AP-HP, French National Reference Centre for Rare Systemic Diseases, Pitié-Salpêtrière Hospital, Paris, France
  2. 2 Paris VI University, UPMC, Sorbonne Universités, Paris, France
  3. 3 Nuclear Medicine Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
  4. 4 Pathology Department, AP-HP, Ambroise Paré Hospital, Versailles University, Boulogne, France
  5. 5 Pharmacy Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
  6. 6 Pathology Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
  7. 7 Cardiovascular Imaging Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
  1. Correspondence to Dr Fleur Cohen-Aubart, Service de Médecine Interne 2, Institut e3m, Groupe Hospitalier Pitié-Salpêtrière, Paris 75 651, France; fleur.cohen{at}psl.aphp.fr

Statistics from Altmetric.com

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterised by long bones and various other organs’ involvements.1 Tissues are infiltrated by CD68+ CD1a− foamy histiocytes.2 Therapeutic options are pegylated interferon-α,3 cladribine,4 mTOR inhibitors5 and anakinra in mild forms of ECD.6 7 Conversely, targeted BRAF or MEK inhibitor therapies are used for refractory or life-threatening ECD manifestations.8 9 All these therapies have frequent side effects. Interferon-α leads to fatigue, cytopenias and autoimmune diseases. Anakinra needs subcutaneous daily injections, with frequent local intolerance. Targeted therapies cause skin cancers, QT allongement, rhabdomyolysis and haemorrhage,10 and we lack long-term safety data with these drugs. Moreover, targeted therapies are not available in all countries. Thus, there is an unmet need for improving treatments in many patients with ECD, particularly in countries where access to targeted therapies is complicated or impossible.

Although our comprehension of this disease has recently moved from inflammatory to clonal myeloproliferative disease,11 the accumulation of pathological histiocytes leads to an increase of several cytokines in blood and affected tissues. Cytokine/chemokine network has been described in ECD lesions, and most of these factors are regulated by tumour necrosis factor alpha (TNF-α), which is also expressed in ECD lesions and serous fluids like pericardial effusion12–14 and has been implicated in ECD pathogenesis in in vitro models.15 Two ECD patients with cardiovascular involvement were successfully treated with infliximab, a TNF-α monoclonal chimeric antibody, achieving an improvement of symptoms, cardiac involvement and function.14 We aim to determine the efficacy of infliximab in a larger series of patients with ECD.

We retrospectively reviewed …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.